Skip to content

US · PCVX · BIOTECHNOLOGY

Vaxcyte, Inc. (PCVX) intrinsic value and stock valuation

$55.39as of 2026-11-21 · Mkt cap 8.07B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vaxcyte, Inc. DCF and intrinsic value

InvestorsCraft values PCVX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PCVX’s statements →

Vaxcyte, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Carlos, CA 94070 vaxcyte.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-766.63M
20172025
Free cash flow
-$-669.29M
20172025
Total equity
$2.69B+50.7% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-923.67M-$-569.55M-$-468.04M-$-232.26M-$-103.67M
Net income-$-766.63M-$-463.93M-$-402.27M-$-223.49M-$-100.08M
EPSd-$-5.63M-$-3.8M-$-4.14M-$-3.44M-$-1.93M
Operating cash flow-$-655.58M-$-452.63M-$-296.79M-$-170.6M-$-121.39M
Capital expenditure-$-13.71M-$-22.43M-$-67.88M-$-5.84M-$-6.55M
Free cash flow-$-669.29M-$-475.05M-$-364.67M-$-176.44M-$-127.95M
Total assets$3.05B$3.51B$1.41B$1.01B$324.3M
Total debt$228.8M$71.1M$29.2M$17.9M$16.8M
Net debt$54.9M-$-316.77M-$-368.23M-$-816.72M-$-52.2M
Total equity$2.69B$3.31B$1.24B$953.6M$284M
Cash and short-term investments$1.56B$1.75B$1.08B$931.4M$246M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$794.3M$476.6M$332.3M$169.5M$78.4M
Selling, general and administrative expenses$129.4M$92.9M$60.7M$39.8M$25.3M
Other expenses$0.00$0.00$75M$23M$0.00
Operating expenses$923.7M$569.6M$468M$232.3M$103.7M
Cost and expenses$923.7M$569.6M$468M$232.3M$103.7M
Interest income$119.7M$110M$62.9M$8.36M$340K
Interest expense$0.00$0.00$0.00$0.00$10K
Depreciation and amortization$24.9M$15.9M$10.2M$9.45M$3.46M
Ebitda-$-741.77M-$-448.08M-$-392.1M-$-214.03M-$-96.61M
Operating income-$-923.67M-$-569.55M-$-468.04M-$-232.26M-$-103.67M
Total other income/expenses, net$157.1M$105.6M$65.8M$8.77M$3.59M
Income before tax-$-766.63M-$-463.93M-$-402.27M-$-223.49M-$-100.08M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-766.63M-$-463.93M-$-402.27M-$-223.49M-$-100.08M
Weighted average shares outstanding$136.1M$122M$97.2M$64.9M$51.9M
Weighted average diluted shares outstanding$136.1M$122M$97.2M$64.9M$51.9M
Balance sheet
20252024202320222021
Cash and short-term investments$1.56B$1.75B$1.08B$931.4M$246M
Net receivables$46.6M$20.7M$3.61M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.63B$1.79B$1.1B$942.6M$256.4M
Property, plant and equipment, net$491.7M$270.2M$110.6M$31.7M$35.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$883.1M$1.39B$162.7M$26.6M$27.1M
Total non-current assets$1.42B$1.72B$312M$63.6M$68M
Total assets$3.05B$3.51B$1.41B$1.01B$324.3M
Accounts payable$70.9M$48.5M$14.6M$9.79M$6.76M
Short-term debt$6.12M$5.89M$7.11M$5.91M$5.28M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$205.8M$140.2M$145.3M$40.5M$28.7M
Long-term debt$222.7M$65.2M$22.1M$12M$11.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$154.7M$65.3M$22.1M$12M$11.6M
Capital lease obligations$111.4M$71.1M$29.2M$17.9M$16.8M
Total liabilities$360.5M$205.5M$167.5M$52.6M$40.3M
Common stock$130K$130K$100K$80K$60K
Retained earnings-$-2.15B-$-1.39B-$-924.39M-$-522.13M-$-298.64M
Accumulated other comprehensive income (loss)$1.59M-$-3.87M$180K-$-360K-$-240K
Total equity$2.69B$3.31B$1.24B$953.6M$284M
Total investments$2.27B$2.75B$845.5M$123.3M$204.1M
Total debt$228.8M$71.1M$29.2M$17.9M$16.8M
Net debt$54.9M-$-316.77M-$-368.23M-$-816.72M-$-52.2M
Cash flow statement
20252024202320222021
Net income-$-766.63M-$-463.93M-$-402.27M-$-223.49M-$-100.08M
Depreciation and amortization$24.9M$15.9M$10.2M$9.45M$3.46M
Stock-based compensation$138.8M$84.8M$48.8M$23.7M$10.7M
Change in working capital-$-3.45M-$-54.9M$81.3M$12.7M-$-37.01M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$19.9M$34.6M$11.2M$2.9M-$-12.47M
Net cash provided by operating activities-$-655.58M-$-452.63M-$-296.79M-$-170.6M-$-121.39M
Investments in property, plant and equipment-$-13.71M-$-22.43M-$-67.88M-$-5.84M-$-6.55M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$437.4M-$-2.01B-$-773.31M$74.6M-$-212.31M
Common stock issued$13M$2.44B$636M$856.5M$13.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.01M$2.45B$639.8M$861.6M$17.8M
Net change in cash-$-213.77M-$-9.36M-$-436.97M$765.7M-$-316.34M
Cash at end of period$175.4M$389.2M$398.6M$835.5M$69.9M
Operating cash flow-$-655.58M-$-452.63M-$-296.79M-$-170.6M-$-121.39M
Capital expenditure-$-13.71M-$-22.43M-$-67.88M-$-5.84M-$-6.55M
Free cash flow-$-669.29M-$-475.05M-$-364.67M-$-176.44M-$-127.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vaxcyte, Inc.

        Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

        CEO
        Grant E. Pickering
        Employees
        507
        Beta
        1.22

        Explore

        Frequently asked questions

        What is the intrinsic value of Vaxcyte, Inc. (PCVX)?

        InvestorsCraft does not currently publish an intrinsic value for PCVX. How the IC value is calculated.

        Is PCVX undervalued?

        InvestorsCraft does not publish an undervaluation signal for PCVX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.